Chinook Therapeutics, Inc. Common Stock
KDNY
KDNY was delisted on the 10th of August, 2023.
87 hedge funds and large institutions have $520M invested in Chinook Therapeutics, Inc. Common Stock in 2015 Q4 according to their latest regulatory filings, with 25 funds opening new positions, 34 increasing their positions, 16 reducing their positions, and 13 closing their positions.
113% more repeat investments, than reductions
Existing positions increased: 34 | Existing positions reduced: 16
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
92% more first-time investments, than exits
New positions opened: 25 | Existing positions closed: 13
50% more capital invested
Capital invested by funds: $347M → $520M (+$173M)
32% more call options, than puts
Call options by funds: $2.18M | Put options by funds: $1.65M
14% more funds holding
Funds holding: 76 → 87 (+11)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$37.6M |
| 2 |
ORI
Oak Ridge Investments
Chicago,
Illinois
|
+$22.7M |
| 3 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$20M |
| 4 |
MAM
Marquette Asset Management
Minneapolis,
Minnesota
|
+$9.51M |
| 5 |
UBS AM
Chicago,
Illinois
|
+$5.34M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
-$27.3M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$16.4M |
| 3 |
Franklin Resources
San Mateo,
California
|
-$13.3M |
| 4 |
FCMI
Foresite Capital Management II
Larkspur,
California
|
-$12.2M |
| 5 |
M&T Bank
Buffalo,
New York
|
-$11M |
KDNY Hedge Fund Activity: Q4 2015 in Review
87 of the 3,812 institutional investors tracked by Wall St. Rank reported a position in Chinook Therapeutics, Inc. Common Stock (KDNY) for Q4 2015, worth a combined $520M — up 50% from $347M a quarter earlier.
Buyers outnumbered sellers: 25 funds opened new KDNY positions and 13 closed out — a net gain of 12 holders — while 34 added to existing stakes and 16 trimmed.
The largest buyer was Vanguard Group, adding an estimated $37.6M. The largest seller was OrbiMed, cutting an estimated $27.3M.
- 87 institutional investors held Chinook Therapeutics, Inc. Common Stock (KDNY) as of Q4 2015, up from 76 in Q3 2015.
- Funds reported $520M of Chinook Therapeutics, Inc. Common Stock stock for Q4 2015, up 50% quarter-over-quarter.
- 25 funds opened new Chinook Therapeutics, Inc. Common Stock positions in Q4 2015 and 13 closed out, a net change of +12 holders.
- The largest Chinook Therapeutics, Inc. Common Stock buyer in Q4 2015 was Vanguard Group, an estimated $37.6M added.
- The largest Chinook Therapeutics, Inc. Common Stock seller in Q4 2015 was OrbiMed, an estimated $27.3M sold.
Based on aggregated 13F filings for Q4 2015.